Takotsubo Syndrome: Does Gender Impact Prognosis?

Takotsubo Syndrome (STT) is characterized by acute cardiac failure which can be reversed in many occasions, but is associated with morbidity and mortality at short and long term. 

Síndrome de Tokotsubo ¿El género tiene influencia en su pronóstico?

It is most frequent among women, especially after menopause. However, gender differences have not been looked into when analyzing the evolution of this cardiomyopathy. 

This was an analysis of the GEIST Registry including 2492 patients with STT. 286 were men (11%).

Men were younger (69 vs. 71, P=0.005), presented more smoking, diabetes, pulmonary disease, and cancer. In addition, they presented more dyspnea and less precordial pain vs. women. 

STT triggering episodes were more physical in men and more emotional in women. 

There were no differences in ECG, but there was in ejection fraction, which was lower in men (38% vs. 40% P=0.001).

Read also: Results of Zotarolimus-Eluting Stents vs Biolimus-Eluting Polymer-Free Stents After 2 Years. Are They Safe in Patients at High Risk for Bleeding?

Men presented more cardiogenic shock (19% vs. 8% P<0.001), inhospital mortality (7% vs. 2% P<0.001) and longer hospital stay.

After propensity score matching 207 pair of patients were left in each group: men had more cardiogenic shock and higher mortality (16% vs 6%, P=0.002 and 8% vs 3%; P=0.003 respectively). 

At long term followup, mortality was 4.3% patient/ years, and was higher in men (10% vs. 3.8% patient /year in the complete series, and 11.5% vs 6.1% patient/year in the matched cohort, respectively). At 60-day followup, mortality was higher in men, but this was not the case in the matched cohort.

Read also: PCI on Native Arteries or Saphenous Vein Grafts: Which Has Better Prognosis?

Multivariable analysis showed that male sex was a predictor of inhospital mortality and mortality at followup. 

Conclusion

Takotsubo syndrome in men involves high risk, and therefore requires more strict control in hospital and after discharge, at long term. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Gender Differences in Takotsubo Syndrome.

Reference: Luca Arcari, J Am Coll Cardiol 2022;79:2085–2093.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...